住院患者使用利奈唑胺致贫血的相关危险因素

目的：探讨住院患者使用利奈唑胺（LZD）治疗期间发生贫血不良反应的相关危险因素。方法：采用回顾性研究，收集2012年5月至2017年5月温州医科大学附属第一医院接受LZD治疗且监测血药浓度的161例住院患者的临床资料，采用logistic回归分析LZD诱发贫血不良反应的相关危险因素。结果：31例（占19.2%）患者被评估为LZD相关性贫血，LZD治疗期间，中重度肾功能不全患者[GFR＜60 mL·（min·1.73 m2）-1]（OR=3.47，95%CI：1.49～8.13，P=0.004）以及药物谷浓度≥7 mg·L-1（OR=2.87，95%CI：1.11～6.93，P=0.024）者发生相关性贫血风险更高。结论：LZD相关性贫血与肾功能及体内药物浓度密切相关。

Risk factors associated with anemia in patients who received linezolid therapy

Objective: To investigate the factors affecting linezolid-induced anemia in hospitalized patients.Methods: A retrospective study was performed to collect data in 161 adult inpatients who received linezolid between May 2012 to May 2017. The risk factors of linezolid-related anemia were confirmed by univariate and multivariate logistic regression. Results: Of all the patients enrolled, linezolid-induced anemia developed in 31 (19.2%) patients during therapy. The incidence of anemia occurred more frequently in patients who received linezolid at concentration≥7 mg·L-1 (OR=2.87, 95%CI: 1.11-6.93, P=0.024) and those with moderate-severe renal impairment [GFR<60 mL·(min·1.73 m2)-1] (OR=3.47, 95%CI: 1.49-8.13, P=0.004). Conclusion: The results of our study indicated that high plasma linezolid concentration and renal impairment significantly affected the development of linezolid-induced anemia.